Literature DB >> 28849249

Protein levels of clusterin and glutathione synthetase in platelets allow for early detection of colorectal cancer.

Sarah Strohkamp1, Timo Gemoll2, Sina Humborg1, Sonja Hartwig3,4, Stefan Lehr3,4, Sandra Freitag-Wolf5, Susanne Becker6, Bo Franzén6, Ralph Pries7, Barbara Wollenberg7, Uwe J Roblick1, Hans-Peter Bruch1, Tobias Keck1, Gert Auer6, Jens K Habermann8,9.   

Abstract

Colorectal cancer (CRC) is one of the most frequent malignancies in the Western world. Early tumor detection and intervention are important determinants on CRC patient survival. During early tumor proliferation, dissemination and angiogenesis, platelets store and segregate proteins actively and selectively. Hence, the platelet proteome is a potential source of biomarkers denoting early malignancy. By comparing protein profiles of platelets between healthy volunteers (n = 12) and patients with early- (n = 7) and late-stage (n = 5) CRCs using multiplex fluorescence two-dimensional gel electrophoresis (2D-DIGE), we aimed at identifying differentially regulated proteins within platelets. By inter-group comparisons, 94 differentially expressed protein spots were detected (p < 0.05) between healthy controls and patients with early- and late-stage CRCs and revealed distinct separations between all three groups in principal component analyses. 54 proteins of interest were identified by mass spectrometry and resulted in high-ranked Ingenuity Pathway Analysis networks associated with Cellular function and maintenance, Cellular assembly and organization, Developmental disorder and Organismal injury and abnormalities (p < 0.0001 to p = 0.0495). Target proteins were validated by multiplex fluorescence-based Western blot analyses using an additional, independent cohort of platelet protein samples [healthy controls (n = 15), early-stage CRCs (n = 15), late-stage CRCs (n = 15)]. Two proteins-clusterin and glutathione synthetase (GSH-S)-featured high impact and were subsequently validated in this independent clinical cohort distinguishing healthy controls from patients with early- and late-stage CRCs. Thus, the potential of clusterin and GSH-S as platelet biomarkers for early detection of CRC could improve existing screening modalities in clinical application and should be confirmed in a prospective multicenter trial.

Entities:  

Keywords:  Clusterin; Colorectal cancer; Early detection; Glutathione synthetase; Platelet protein

Mesh:

Substances:

Year:  2017        PMID: 28849249     DOI: 10.1007/s00018-017-2631-9

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  53 in total

Review 1.  The platelet release reaction: granules' constituents, secretion and functions.

Authors:  F Rendu; B Brohard-Bohn
Journal:  Platelets       Date:  2001-08       Impact factor: 3.862

2.  Tumor-cell-induced platelet aggregation is a glycoprotein-dependent and lipoxygenase-associated process.

Authors:  E Bastida; L Almirall; A Ordinas
Journal:  Int J Cancer       Date:  1987-06-15       Impact factor: 7.396

3.  Overexpression of cofilin 1 can predict progression-free survival in patients with epithelial ovarian cancer receiving standard therapy.

Authors:  Sadako Nishimura; Hiroshi Tsuda; Fumio Kataoka; Tokuzo Arao; Hiroyuki Nomura; Tatsuyuki Chiyoda; Nobuyuki Susumu; Kazuto Nishio; Daisuke Aoki
Journal:  Hum Pathol       Date:  2011-01-14       Impact factor: 3.466

4.  Comparison of guaiac and immunological fecal occult blood tests in colorectal cancer screening: the patient perspective.

Authors:  Marije Deutekom; Leo G M van Rossum; Anne F van Rijn; Robert J F Laheij; Paul Fockens; Patrick M M Bossuyt; Evelien Dekker; Jan B M J Jansen
Journal:  Scand J Gastroenterol       Date:  2010-06-21       Impact factor: 2.423

5.  Prohibitin and cofilin are intracellular effectors of transforming growth factor beta signaling in human prostate cancer cells.

Authors:  Beibei Zhu; Kei Fukada; Haining Zhu; Natasha Kyprianou
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

6.  Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK.

Authors:  Carolin Tonus; Gero Neupert; Markus Sellinger
Journal:  World J Gastroenterol       Date:  2006-11-21       Impact factor: 5.742

7.  Differential expression of up-regulated cofilin-1 and down-regulated cofilin-2 characteristic of pancreatic cancer tissues.

Authors:  Yufeng Wang; Yasuhiro Kuramitsu; Tomio Ueno; Nobuaki Suzuki; Shigefumi Yoshino; Norio Iizuka; Xiulian Zhang; Masaaki Oka; Kazuyuki Nakamura
Journal:  Oncol Rep       Date:  2011-09-05       Impact factor: 3.906

Review 8.  Aspirin and Cancer.

Authors:  Paola Patrignani; Carlo Patrono
Journal:  J Am Coll Cardiol       Date:  2016-08-30       Impact factor: 24.094

9.  Application of selected reaction monitoring for multiplex quantification of clinically validated biomarkers in formalin-fixed, paraffin-embedded tumor tissue.

Authors:  Todd Hembrough; Sheeno Thyparambil; Wei-Li Liao; Marlene M Darfler; Joseph Abdo; Kathleen M Bengali; Stephen M Hewitt; Richard A Bender; David B Krizman; Jon Burrows
Journal:  J Mol Diagn       Date:  2013-05-11       Impact factor: 5.568

10.  Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma.

Authors:  Graham J Caine; Gregory Y H Lip; Paul S Stonelake; Peter Ryan; Andrew D Blann
Journal:  Thromb Haemost       Date:  2004-07       Impact factor: 5.249

View more
  8 in total

1.  Perioperative changes of inflammation-based biomarker for predicting the prognosis in colorectal cancer patients: a retrospective analysis.

Authors:  Xie Ya; Fan Wenbin; Yan Wenfeng; Wu Gang; Ren Ke; Zhou Yang; Tao Yong
Journal:  Prz Gastroenterol       Date:  2019-12-20

2.  Decreased circulating clusterin reflects severe liver complications after hepatoportoenterostomy of biliary atresia.

Authors:  Wanvisa Udomsinprasert; Yong Poovorawan; Voranush Chongsrisawat; Paisarn Vejchapipat; Sittisak Honsawek
Journal:  Sci Rep       Date:  2020-11-12       Impact factor: 4.379

3.  The canine activated platelet secretome (CAPS): A translational model of thrombin-evoked platelet activation response.

Authors:  Signe E Cremer; James L Catalfamo; Robert Goggs; Stefan E Seemann; Annemarie T Kristensen; Paulina B Szklanna; Patricia B Maguire; Marjory B Brooks
Journal:  Res Pract Thromb Haemost       Date:  2020-12-03

4.  Inhibition Lysosomal Degradation of Clusterin by Protein Kinase D3 Promotes Triple-Negative Breast Cancer Tumor Growth.

Authors:  Yan Liu; Yehui Zhou; Xinxing Ma; Liming Chen
Journal:  Adv Sci (Weinh)       Date:  2021-01-06       Impact factor: 16.806

Review 5.  Platelets as messengers of early-stage cancer.

Authors:  Siamack Sabrkhany; Marijke J E Kuijpers; Mirjam G A Oude Egbrink; Arjan W Griffioen
Journal:  Cancer Metastasis Rev       Date:  2021-02-26       Impact factor: 9.264

6.  Evaluation of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio on Predicting Responsiveness to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients.

Authors:  Maoxi Liu; Yi Feng; Yixun Zhang; Haiyi Liu
Journal:  Biomed Res Int       Date:  2022-09-28       Impact factor: 3.246

7.  Alterations of the Platelet Proteome in Lung Cancer: Accelerated F13A1 and ER Processing as New Actors in Hypercoagulability.

Authors:  Huriye Ercan; Lisa-Marie Mauracher; Ella Grilz; Lena Hell; Roland Hellinger; Johannes A Schmid; Florian Moik; Cihan Ay; Ingrid Pabinger; Maria Zellner
Journal:  Cancers (Basel)       Date:  2021-05-08       Impact factor: 6.639

8.  PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy.

Authors:  Verena Rolfes; Christian Idel; Ralph Pries; Bernardo S Franklin; Barbara Wollenberg; Kirstin Plötze-Martin; Jens Habermann; Timo Gemoll; Sabine Bohnet; Eicke Latz; Julika Ribbat-Idel
Journal:  Oncotarget       Date:  2018-06-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.